Colby Pharmaceutical Announces SBIR Award for JunD Oncoprotein-Androgen Receptor (AR) Interaction Inhibitor Drugs in Novel Prostate Cancer Therapy.
SAN JOSE, Calif. -- Colby Pharmaceutical Company (Colby), a private San Jose, CA biopharmaceutical company, announced that it received a National Cancer Institute (NCI) SBIR funding award for small molecule inhibitors of interactions between Androgen Receptor (AR) Protein with JunD Oncoprotein for treatment of prostate cancer (PCa).
Advanced hormone refractory metastatic prostate cancer (CRPCa) is among the leading causes of US cancer deaths and most conventional therapies are only modestly effective against CRPCa. Colby's Chief Scientific Officer, Hirak Basu PhD and SAB Co-Chairman, George Wilding MD, in collaboration with researchers at the University of Wisconsin-Madison, showed hydrogen peroxide production from enzymatic oxidation of spermine and spermidine in human PCa cells responsible for PCa progression to CRPCa. Drs. Basu, Wilding and collaborators demonstrated in human PCa that activated AR Protein physically binds JunD Oncoprotein to induce specific enzymes catalyzing spermine/spermidine oxidation. The SBIR focuses on new chemical entity drugs specifically blocking JunD-AR protein-protein interactions and, thus, blocking hydrogen peroxide production in human PCa tumor cells and inhibiting progression to CRPCa.
Colby's Chief Executive Officer David Zarling PhD MBA stated, "This SBIR grant award independently validates UW-Madison's/Colby's development of small molecule novel therapeutics inhibiting human PCa tumor cell transcriptional activation in the absence of Androgen. With this NCI SBIR award and the recent merger with Othera Pharmaceuticals, Colby is adding to its pipeline of promising NCE cancer drug candidates and products for potential partnering."
About Colby Pharmaceutical Company
Colby, a privately held biopharmaceutical company based in San Jose, CA working in collaboration with research teams at Stanford Medical School, CA and University of Wisconsin-Madison Carbone Cancer Center, WI. Colby is developing new oral small molecule transcription factor inhibitors, anti-inflammation activator and immune activator biopharmaceuticals for treatment of advanced cancer, chronic inflammation, pain, infection, and neurodegeneration. Colby's lead molecular targeted therapies are newly discovered proprietary small molecules targeting novel pathways for treatment of hard to treat infection, immune dysfunction, hepatocellular carcinoma and recurrent prostate carcinoma, and cancer pain, all with minimal toxicities and side effects.
|Printer friendly Cite/link Email Feedback|
|Date:||Oct 1, 2012|
|Previous Article:||Iams Home 4 the Holidays Set to Feed More Homeless Pets Than Ever Before.|
|Next Article:||Foot Locker Selects LightHaus to Improve Conversion Rates, Deliver Reliable Customer Insights.|